Type II DNA topoisomerase inhibitor. Disrupts DNA synthesis and repair and induces damage by DNA cross-linking. Also inhibits PIM1 kinase (IC50
= 51 nM). Immunomodulatory, antineoplastic and chemotherapeutic agent. Also USP11 inhibitor (IC50
= 3.15 μ
M). Induces cell death of pancreatic cancer cell lines expressing wild-type BRCA2
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling.
Wan et al.
Mitoxantrone: a review of its uses in multiple sclerosis.
Scott and Figgit
CNS Drugs., 2004;18:379
Mitoxantrone affects topoisomerase activities in human breast cancer cells.
Crespi et al.
Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival.
Burkhart et al.
Mol.Cancer Res., 2013;11:901